European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Cheplapharm Arzneimittel GmbH, Greifswald, Germany

Watch
Cheplapharm Arzneimittel GmbH

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €/month

Learn more
Learn more
View plans

Name

Cheplapharm Arzneimittel GmbH

Identification

Ut
District Court of Stralsund HRB 5896
Sirul
Siren 798504197
Ccrcom
The Brønnøysund Register Centre 825696822
Siret
Siret 79850419700012
Lei
529900ONXKBELT7EW052
EUID
DEN1209V.HRB5896

Address

Ziegelhof 24, 17489 Greifswald, Germany
Mesekenhagen, Germany

Corporate purpose

- The manufacture and distribution of pharmaceutical preparations, food, personal care products and medical devices. - The Company is authorized to acquire similar or similar companies at home and abroad, to participate in such, to assume their personal liability and representation and to establish branches at home and abroad.

History

Persons

Marketing & Tech

Merger & Acquisition & Control

Network

Loading network

Legal Structure

Current legal representatives Legal form information · Proxy policies Premium
Premium
7Managing Director
11Authorized signatory (ppa)
Upgrade to unlock all features

Premium plans starting from €/month

Learn more View plans
Learn more View plans
CSV export

Quarterly Exports in CSV

Now available in CSV format and optimized for applications in AI and Analytics:
North Data's quarterly exports have become the industry standard for company information.

Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
One known shareholder
Portfolio and Investments
2 known active shareholdings
Upgrade to unlock all features

Premium plans starting from €/month

Learn more View plans
Learn more View plans

Publications

18 Jun 2026
Managing Director: Martin Krämer
4 Jun 2026
No longer Authorized signatory (ppa): José Aguilar Barroso
13 May 2026
Managing Director: Markus Peterseim
24 Mar 2026
No longer Authorized signatory (ppa): Juliane Nießen-Erkel
17 Feb 2026 via Cheplapharm SE also 02/02/2026, 12/02/2025, 27/01/2025
Shareholder: Cheplapharm SE
6 Feb 2026
No longer Authorized signatory (ppa): Tamas Szoga
11 Sept 2025
Wordmark: “HYDREA“
27 May 2025
Managing Director: Edeltraud M. Lafer, K. Parssanedjad · Authorized signatory (ppa) (6)
11 Feb 2025
No longer Authorized signatory (ppa): Jan Peter Klumb · Authorized signatory (ppa) (5)
10 Dec 2024
Managing Director: Sebastian Braun
28 Nov 2024
Managing Director: Arutyun Gevorkyan
12 Nov 2024
Authorized signatory (ppa): José Aguilar Barroso · No longer Authorized signatory (ppa): Marten Hein
19 Aug 2024
No longer Managing Director: Klaus Köhl
23 Jul 2024
Authorized signatory (ppa): Patrick Katsoulis
Year 2024 in Dpmam
6 trademark filings (3 wordmarks, 1 figurative mark, 2 word figurative marks): CHEPLA, CHEPLANET, CHEPLAPHARM …
4 Mar 2024
No longer Managing Director: Gerrit Amthor · No longer Authorized signatory (ppa) (1)
23 Jan 2024 via Cheplapharm SE also 09/02/2023, 21/03/2022
Shareholder: Cheplapharm AG
3 Jan 2024
No longer Managing Director: Sebastian Braun
7 Nov 2023
Company statute
21 Sept 2023
Original document: “Gesellschaftsvertrag / Satzung / Statut“
11 Aug 2023
Bekanntmachung gemäß § 97 Abs. 1 AktG über die Bildung und Zusammensetzung des Aufsichtsrats der Cheplapharm Arzneimittel GmbH
12 May 2023
Antitrust Investigation: Cheplapharm Arzneimittel GmbH, USA
19 Apr 2023
Wordmark: “YOCOBIS“
23 Mar 2023
Managing Director: Gerrit Amthor · No longer Authorized signatory (ppa) (1)
10 Feb 2023
Figurative mark: “Figurative“
11 Jan 2023
Authorized signatory (ppa): Jing Lin · No longer Managing Director: Patrick König
20 Dec 2022
Merger: Herkules Invest 336 AS
13 Dec 2022
Managing Director: Klaus Köhl
4 Aug 2022
Merger: c/o Intertrust (Norway) AS, Cheplapharm Arzneimittel GmbH
25 Jul 2022
Authorized signatory (ppa): Juliane Nießen-Erkel
22 Jul 2022
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
1 Jul 2022
Authorized signatory (ppa): Torsten Buchbach · No longer Authorized signatory (ppa) (2)
19 Jun 2022
Corporate Purpose
19 Jun 2022
Corporate Purpose
19 Jun 2022
Corporate Purpose
19 Apr 2022
Consolidated Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020 · 9 Shareholdings (9 companies)
16 Mar 2022
Managing Director: K. Parssanedjad · No longer Managing Director: Jens Rothstein · Authorized signatory (ppa) (3)
16 Mar 2022
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020 · Shareholder (4 companies)
16 Mar 2022
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020 · 4 Shareholdings (4 companies)
7 Mar 2022
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019 · 3 Shareholdings: Cheplapharm France SAS, Glenwood Verwaltung II UG, Med-Tec Holding …
17 Sept 2021
Wordmark: “ACTOS“
17 Sept 2021
Wordmark: “COMPETACT“
2 Jul 2021
Profit Transfer: CheplaFinance 2 GmbH · Control: CheplaFinance 2 GmbH
22 Jun 2021
Profit Transfer: CheplaFinance 2 GmbH · Control: CheplaFinance 2 GmbH
7 Jun 2021
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
21 Apr 2021
Managing Director: K. Parssanedjad
26 Mar 2021
Share­holder agreement
19 Mar 2021
Managing Director: Patrick König · Authorized signatory (ppa): Christian Ely · No longer Authorized signatory (ppa): Patrick König
16 Mar 2021
Original document: “Gesellschaftsvertrag / Satzung / Statut“
17 Jan 2021
Corporate Purpose
4 Jan 2021
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019 · 3 Shareholdings: Cheplapharm France SAS, Glenwood Verwaltung II UG, Med-Tec Holding …
29 Jun 2020
Wordmark: “ACTOS“
29 Jun 2020
Wordmark: “COMPETACT“
27 Mar 2020
Persons
19 Mar 2020
Authorized signatory (ppa) (1)
25 Feb 2020
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018 · Shareholder (5 companies)
6 Feb 2020
Capital: €25,000 · Corporate Purpose
10 Jan 2020
Authorized signatory (ppa): Patrick König
8 Jan 2020
Profit Transfer: CheplaFinance 2 GmbH · Control: CheplaFinance 2 GmbH
9 Dec 2019
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
26 Sept 2019
Original document: “Liste der Gesellschafter“
Year 2019 in Dpmam
71 trademark filings: AQUAPHOR, Aponal, Baldrian-Dispert, Boxogetten, CYMEVEN, CalciAPS D3, Calcivit D, Calcivit F, Cimi, Cimifuga, Convacard, DISTRANEURIN, DYNORM, Dilatrend, ETOPOPHOS …
27 Aug 2019
Authorized signatory (ppa) (1)
13 Aug 2019
Acquisition (3 companies) · Break-up (3 companies)
25 Jul 2019
Original document: “Liste der Gesellschafter“
25 Jul 2019
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
14 Jun 2019
Wordmark: “CHEPLA“
14 Mar 2019
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017 · 6 Shareholdings (6 companies)
21 Jan 2019
Authorized signatory (ppa): Jan Peter Klumb
26 Nov 2018
No longer Authorized signatory (ppa) (1)
Year 2018 in Dpmam
1 wordmark: CYMEVEN, Calcivit D, Calcivit F, DISTRANEURIN, DYNORM, Ephelidin, VEPESID, YOCOBIS …
29 Oct 2018
Share­holder agreement
8 Oct 2018
Original document: “Gesellschaftsvertrag / Satzung / Statut“
4 Oct 2018
Authorized signatory (ppa): Katrin Bäsell
14 May 2018
Wordmark: “PIMAFUCIN“
14 May 2018
Wordmark: “ZINERYT“
4 May 2018
Managing Director: Jens Rothstein · Authorized signatory (ppa): Patrick König
23 Apr 2018
Wordmark: “ATACAND“
14 Mar 2018
Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016 · 4 Shareholdings (4 companies)
26 Feb 2018
Managing Director: Edeltraud M. Lafer · No longer Authorized signatory (ppa) (1)
29 Jan 2018
No longer Authorized signatory (ppa) (1)
Year 2017 in Dpmam
6 trademark filings: Dilatrend, ETOPOPHOS, FUNGIZONE, KP-Kapseln, Quantalan …
12 Dec 2017
Authorized signatory (ppa) (1)
28 Aug 2017
Original document: “Liste der Gesellschafter“
10 Aug 2017
Authorized signatory (ppa) (1)
12 Jun 2017
Share­holder agreement
7 Jun 2017
Authorized signatory (ppa): Manfred Jantsch
13 Mar 2017
Annual report for the year ending 31/12/2015 · Balance sheet for 31/12/2015 · Earnings statement for 31/12/2015 · 4 Shareholdings (4 companies)
20 Feb 2017
Original document: “Gesellschaftsvertrag / Satzung / Statut“
13 Feb 2017
Address
26 Jan 2017
Managing Director: Edeltraud M. Lafer
2 Jan 2017 via Cheplapharm France SAS
President: Cheplapharm France SAS
Year 2016 in Dpmam
1 wordmark: ACTOS, Acidrine, COMPETACT …
25 Oct 2016
Wordmark: “SUPRECUR“
30 Sept 2016
Authorized signatory (ppa) (3)
14 Jul 2016
Share­holder agreement · Corporate Purpose
30 Jun 2016
Original document: “Liste der Gesellschafter“
30 Jun 2016
Original document: “Gesellschaftsvertrag / Satzung / Statut“
29 Mar 2016
Annual report for the year ending 31/12/2014 · Balance sheet for 31/12/2014 · Earnings statement for 31/12/2014 · Shareholder (4 companies)
14 Jan 2016
Figurative mark
Year 2015 in Dpmam
18 trademark filings: Boxbergal, CHEPLAREN, Calcivit F, ETOPOPHOS, FUNGIZONE, Octadon, Prostadil, Psorifug, Quantalan, Urorenal, VASCAL, pertenso …
6 May 2015
Annual report for the year ending 31/12/2013 · Balance sheet for 31/12/2013 · Earnings statement for 31/12/2013 · Shareholding: Verbundenen Unternehmen
6 Feb 2015
Wordmark: “VESANOID“
14 Jan 2015
Managing Director: Bianca Yasmin Juha · No longer Authorized signatory (ppa): Bianca Yasmin Juha · No longer Managing Director (1)
Year 2014 in Dpmam
13 trademark filings: ACTOS, CYMEVEN, Calcivit F, DYNORM, Dilatrend, POTABA, TANGO, YOCOBIS, YOCORAL, Yocon-Glenwood …
8 Jul 2014
Wordmark: “DUOMOX“
16 May 2014
Annual report for the year ending 31/12/2012 · Balance sheet for 31/12/2012
Year 2013 in Dpmam
30 trademark filings: Aponal, CalciAPS D3, Cimi, Cimifuga, Dialax, Epurea, GRÜNLICHT, KP-Kapseln, Magnesium Tonil, Metifex, Muskelgold, Normalip, PALMISAN, Pe-Ce, ROTOKAN …
15 Oct 2013 in France
Reg­is­tra­tion: 15/10/2013 · Address · Legal form: Société étrangère non immatriculée au RCS · Name: CHEPLAPHARM ARZNEIMITTEL GMBH · Segment clas­si­fi­ca­tion
24 May 2013
Managing Director: Sebastian Braun · Authorized signatory (ppa): Bianca Yasmin Juha
12 Apr 2013
Annual report for the year ending 31/12/2011 · Balance sheet for 31/12/2011 · Shareholding: Walter Ritter GmbH & Co. KG
6 Feb 2013
Annual report for the year ending 31/12/2010 · Balance sheet for 31/12/2010 · Shareholding: Verbundenen Unternehmen
Year 2012 in Dpmam
16 trademark filings: BOXOCALM, BOXODOLOR, BOXOSED, CYMEVEN, Caye-Balsam, DISTRANEURIN, GELUSIL LAC, Gelusil, Metifex, Octadon …
12 Mar 2012
Annual report for the year ending 31/12/2010 · Balance sheet for 31/12/2010
6 Jan 2012
Authorized signatory (ppa) (1)
5 Jan 2012
Annual report for the year ending 31/12/2008 · Balance sheet for 31/12/2008
5 Jan 2012
Annual report for the year ending 31/12/2009 · Balance sheet for 31/12/2009
Year 2011 in Dpmam
14 trademark filings: ACTOS, CYMEVEN, D-CalciAPS, DYNORM, Dilatrend, E-Tonil, Fungiderm, Larylin, Quantalan, St. Jakobs-Balsam …
Year 2011 in Euipotm
4 wordmarks: DISTRANEURIN, HEMINEVRIN, RIVOTRIL, XENICAL
13 Dec 2010
Annual report for the year ending 31/12/2009 · Balance sheet for 31/12/2009
2 Dec 2010
Wordmark: “CHEPLAPHARM“
Year 2010 in Dpmam
46 trademark filings: BOXONAL, Boxosan, CalciAPS D3, Cimifuga, D-CalciAPS, DISTRANEURIN, E-Tonil, Epurea, Equiday, FEMISANA, Fungiderm, KP-Kapseln, Magnesium Tonil, Muskelgold, PC 30 …
30 Jul 2010
Authorized signatory (ppa) (1)
1 Dec 2009
Annual report for the year ending 31/12/2008 · Balance sheet for 31/12/2008
Year 2009 in Dpmam
28 trademark filings: AQUAPHOR, BOXOLIP, Baldrian-Dispert, Calcivit F, Dialax, Fungiderm, Normalip, PC 30, Pe-Ce, Quantalan, Silberne Boxberger, Vitagutt, boxo …
16 Aug 2009
Wordmark: “TALIDAT“
23 Jun 2009
Original document: “Liste der Gesellschafter“
23 Jun 2009
Original document: “Liste der Gesellschafter“
15 Jun 2009
Wordmark: “UBRETID“
17 Apr 2009
Managing Director (1)
6 Jan 2009
Original document: “Liste der Gesellschafter“
6 Jan 2009
Original document: “Liste der Gesellschafter“
6 Jan 2009
Original document: “Liste der Gesellschafter“
Year 2008 in Euipotm
10 trademark filings (8 wordmarks, 1 figurative mark, 1 word figurative mark): ACTOCORTINA, COMPETACT, MASTICAL, ONE-ALPHA, SEROQUEL, SEROQUEL XR, TANDEMACT, TAXOL …
Year 2008 in Dpmam
1 wordmark: Aponal, CalciAPS D3, Cimi, Cimifuga, D-CalciAPS, E-Tonil, EUMEL-BULL, Ephelidin, Epurea, GRÜNLICHT, KP-Kapseln, Magnesium Tonil, Muskelgold, ROTOKAN, boxo …
8 Feb 2008
Annual report for the year ending 31/12/2006 · Balance sheet for 31/12/2006
31 Jan 2008
Annual report for the year ending 31/12/2006 · Balance sheet for 31/12/2006
Year 2007 in Dpmam
1 wordmark: AQUAPHOR, BOXONAL, Baldrian-Dispert, CalciAPS D3, Cimi, D-CalciAPS, E-Tonil, GELUSIL LAC, Gelusil, Magnesium Tonil, Reisegold, Silberne Boxberger, Urorenal, YOCOBIS, boxo …
5 Mar 2007
Annual report for the year ending 31/12/2005
Year 2006 in Dpmam
54 trademark filings: Acidrine, BOXOCALM, BOXODOLOR, BOXOLIP, BOXOSED, Boxbergal, Boxogetten, Boxosan, CHEPLAREN, CalciAPS D3, Convacard, D-CalciAPS, Dialax, E-Tonil, Equiday …
7 Jun 2006
Reg­is­tra­tion · Managing Director: Sebastian Braun · ppa (1) · Capital: €25,000 · Seat: Mesekenhagen · Legal form: GmbH · Name: Cheplapharm Arzneimittel GmbH · Corporate Purpose
Year 2005 in Dpmam
2 wordmarks: ACTOS, CYMEVEN, GRÜNLICHT, Larylin, Okasa, PREKURSAN, Prostadil, Redaxa, Vitagutt, YOCORAL …
2 Feb 2005
Patent: Pharmazeutische Zusammensetzung Enthaltend einen Lipase - Inhibitor und Glucomannan
There are no publications matching your search.

Mentions

13 Apr 2026 in Ler
Direct parent
13 Apr 2026 in Ler
Ultimate parent
14 Feb 2026 in Rne
Reg­is­tra­tion: 15/10/2013 · Segment clas­si­fi­ca­tion · Corporate Purpose
9 Dec 2024 in Hrcdd
Profit Transfer: Cheplapharm International Holding GmbH
8 Aug 2023 in Hrdk also 04/05/2023, 29/06/2021, 14/04/2021
Cheplapharm International Holding GmbH: “Liste der Gesellschafter“
10 Dec 2021 in Bmjfbv
Shareholding: VORGE sechste PGG GmbH
4 Dec 2020 in Hrdk also 25/11/2020, 06/11/2018
Med-Tec Holding GmbH: “Liste der Gesellschafter“
11 Sept 2020 in Bmjfbv also 11/01/2020
Shareholding: zr pharma& GmbH
26 Aug 2019 in Hrcdd
Limited Partner: Walter Ritter GmbH & Co.KG
Year 2019 in Hrdk
2 Shareholdings: WR Group GmbH, Med-Tec Holding GmbH
26 Sept 2017 in Hrdk
CLEARUM GmbH: “Liste der Gesellschafter“
14 Oct 2008 in Hrdk
WR Group GmbH: “Liste der Gesellschafter“
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.